You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

E7080

Showing 1 - 25 of 163
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma Trial in Rochester

Completed
Has Results
  • Malignant Adrenal Gland Pheochromocytoma
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
Sep 28, 2022

Advanced Carcinoid Tumor, Digestive System Neuroendocrine Tumor, Multiple Endocrine Neoplasia Type 1 Trial in Houston

Recruiting
  • Advanced Carcinoid Tumor
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +16 more
Oct 14, 2022

High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous

Recruiting
  • High Grade Fallopian Tube Serous Adenocarcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Solid Tumor Trial in Beijing, Harbin (lenvatinib)

Completed
  • Solid Tumor
  • Beijing, Beijing, China
  • +1 more
Sep 27, 2021

Advanced Melanoma Trial in Worldwide (lenvatinib, pembrolizumab)

Active, not recruiting
  • Advanced Melanoma
  • Chandler, Arizona
  • +22 more
Jul 21, 2022

Malignant Melanoma Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
  • Malignant Melanoma
  • Pembrolizumab
  • +2 more
  • Beijing, Beijing, China
  • +10 more
Dec 22, 2021

Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic

Active, not recruiting
  • Columnar Cell Variant Thyroid Gland Papillary Carcinoma
  • +25 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Torrance, California
  • +6 more
Jan 12, 2023

Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8

Recruiting
  • Recurrent Hepatocellular Carcinoma
  • +7 more
  • Scottsdale, Arizona
  • +1 more
Jun 16, 2022

Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation Trial in Japan (Pembrolizumab, Lenvatinib, Carboplatin)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • EGFR Activating Mutation
  • Urayasu, Chiba, Japan
  • +9 more
Jul 19, 2022

Tumors Trial (Favezelimab, Pembrolizumab, Oxaliplatin)

Active, not recruiting
  • Neoplasms
  • Favezelimab
  • +7 more
  • (no location specified)
Apr 11, 2022

Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Trial in Columbus (Lenvatinib Mesylate,

Completed
  • Fallopian Tube Carcinoma
  • +3 more
  • Lenvatinib Mesylate
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 5, 2022

Biliary Tract Cancer Trial in Changchun (Lenvatinib, PD-1 inhibitors)

Recruiting
  • Biliary Tract Cancer
  • Changchun, Jilin, China
    Liu Bo
Aug 18, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Thyroid Cancer Trial in Philadelphia (Lenvatinib, Everolimus)

Suspended
  • Thyroid Cancer
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Oct 7, 2021

Advanced Solid Tumors Trial in Boston (Golvatinib, Lenvatinib)

Terminated
Has Results
  • Advanced Solid Tumors
  • Boston, Massachusetts
  • +1 more
May 12, 2021

Untreated Advanced or Recurrent Thymic Carcinomas Trial in Chuo (MK-3475, Lenvatinib, Carboplatin)

Not yet recruiting
  • Untreated Advanced or Recurrent Thymic Carcinomas
  • Chuo, Tokyo, Japan
    National Cancer Center Hospital
Apr 16, 2023

Overall Survival in Unresectable Hepatocellular Carcinoma

Completed
  • Carcinoma, Hepatocellular
  • +3 more
  • Osaka, Japan
  • +1 more
Mar 7, 2022

Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 17, 2022

Endometrial Tumors Trial in China (Lenvatinib, Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Endometrial Neoplasms
  • Hefei, Anhui, China
  • +21 more
May 6, 2022

Nonsquamous NSCLC Trial in China (Pembrolizumab, Carboplatin, Cisplatin)

Active, not recruiting
  • Nonsquamous Non-small Cell Lung Cancer
  • Pembrolizumab
  • +5 more
  • Beijing, Beijing, China
  • +18 more
Dec 2, 2021

Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Trial in United States

Recruiting
  • Metastatic Renal Cell Carcinoma
  • +3 more
  • Avelumab
  • +7 more
  • Danville, Illinois
  • +4 more
Jul 29, 2022

Hepatocellular Carcinoma Trial in Beijing (Camrelizumab, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Please Select, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jun 8, 2022

Unresectable Hepatocellular Carcinoma (HCC) Trial in Harbin, Shanghai (Lenvatinib)

Completed
  • Unresectable Hepatocellular Carcinoma (HCC)
  • Harbin, Heilongjiang, China
  • +2 more
Mar 30, 2021

Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma Trial in Atlanta

Terminated
  • Differentiated Thyroid Gland Carcinoma
  • +2 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jun 25, 2021